Literature DB >> 21849099

Use of the self-controlled case-series method in vaccine safety studies: review and recommendations for best practice.

Y G Weldeselassie1, H J Whitaker, C P Farrington.   

Abstract

The self-controlled case-series method was originally developed to investigate potential associations between vaccines and adverse events, and is now commonly used for this purpose. This study reviews applications of the method to vaccine safety investigations in the period 1995-2010. In total, 40 studies were reviewed. The application of the self-controlled case-series method in these studies is critically examined, with particular reference to the definition of observation and risk periods, control of confounders, assumptions and potential biases, methodological and presentation issues, power and sample size, and software. Comparisons with other study designs undertaken in the papers reviewed are also highlighted. Some recommendations are presented, with the emphasis on promoting good practice.

Mesh:

Substances:

Year:  2011        PMID: 21849099     DOI: 10.1017/S0950268811001531

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  35 in total

1.  Pharmacoepidemiology.

Authors:  Stephen J W Evans
Journal:  Br J Clin Pharmacol       Date:  2012-06       Impact factor: 4.335

2.  Risk of Intussusception After Rotavirus Vaccination.

Authors:  Judith Koch; Thomas Harder; Rüdiger von Kries; Ole Wichmann
Journal:  Dtsch Arztebl Int       Date:  2017-04-14       Impact factor: 5.594

3.  The safety of live attenuated influenza vaccine in children and adolescents 2 through 17 years of age: A Vaccine Safety Datalink study.

Authors:  Matthew F Daley; Christina L Clarke; Jason M Glanz; Stanley Xu; Simon J Hambidge; James G Donahue; James D Nordin; Nicola P Klein; Steven J Jacobsen; Allison L Naleway; Michael L Jackson; Grace Lee; Jonathan Duffy; Eric Weintraub
Journal:  Pharmacoepidemiol Drug Saf       Date:  2017-11-17       Impact factor: 2.890

4.  Risk of Guillain-Barré syndrome following herpes zoster, United States, 2010-2018.

Authors:  Tara C Anderson; Jessica W Leung; Rafael Harpaz; Kathleen L Dooling
Journal:  Hum Vaccin Immunother       Date:  2021-12-02       Impact factor: 3.452

5.  Hospitalizations for chronic conditions following hurricanes among older adults: A self-controlled case series analysis.

Authors:  Sue Anne Bell; John P Donnelly; Wang Li; Matthew A Davis
Journal:  J Am Geriatr Soc       Date:  2022-02-16       Impact factor: 7.538

6.  Enhancing global vaccine pharmacovigilance: Proof-of-concept study on aseptic meningitis and immune thrombocytopenic purpura following measles-mumps containing vaccination.

Authors:  Silvia Perez-Vilar; Daniel Weibel; Miriam Sturkenboom; Steven Black; Christine Maure; Jose Luis Castro; Pamela Bravo-Alcántara; Caitlin N Dodd; Silvana A Romio; Maria de Ridder; Swabra Nakato; Helvert Felipe Molina-León; Varalakshmi Elango; Patrick L F Zuber
Journal:  Vaccine       Date:  2017-05-27       Impact factor: 3.641

7.  Acute disseminated encephalomyelitis and routine childhood vaccinations - a self-controlled case series.

Authors:  T J Martin; M Fahey; M Easton; H J Clothier; R Samuel; N W Crawford; J P Buttery
Journal:  Hum Vaccin Immunother       Date:  2021-04-09       Impact factor: 3.452

8.  COVID-19 and Risk of Acute Ischemic Stroke Among Medicare Beneficiaries Aged 65 Years or Older: Self-Controlled Case Series Study.

Authors:  Quanhe Yang; Xin Tong; Mary G George; Anping Chang; Robert K Merritt
Journal:  Neurology       Date:  2022-02-03       Impact factor: 9.910

Review 9.  Case-only designs in pharmacoepidemiology: a systematic review.

Authors:  Sandra Nordmann; Lucie Biard; Philippe Ravaud; Marina Esposito-Farèse; Florence Tubach
Journal:  PLoS One       Date:  2012-11-16       Impact factor: 3.240

10.  Risk of Guillain-Barré syndrome after 2010-2011 influenza vaccination.

Authors:  Francesca Galeotti; Marco Massari; Roberto D'Alessandro; Ettore Beghi; Adriano Chiò; Giancarlo Logroscino; Graziella Filippini; Maria Donata Benedetti; Maura Pugliatti; Carmela Santuccio; Roberto Raschetti
Journal:  Eur J Epidemiol       Date:  2013-03-31       Impact factor: 8.082

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.